<Table 1>
 <caption text="

         Coronary Vasomotion Disorders International Study (COVADIS) clinical criteria for the diagnosis of microvascular angina.
        
">
 </caption>
 <row row="0">
  <cell col="0" row="0" text="
           COVADIS criteria for microvascular angina
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="1">
  <cell col="0" row="1" text="
           1. Symptoms of myocardial ischemia
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="1" text="



              •
             

              Effort and/or rest angina
             



              •
             

              Angina equivalents (i.e. shortness of breath)
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="2">
  <cell col="0" row="2" text="
           2. Absence of obstructive CAD (&gt;50% diameter reduction and/or FFR &lt;0.80) by either:
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="2" text="



              •
             

              CT coronary angiography (CTCA)
             



              •
             

              Invasive coronary angiography
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="3">
  <cell col="0" row="3" text="
           3. Objective evidence of myocardial ischemia
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="3" text="



              •
             

              Ischemic ECG changes during an episode of chest pain
             



              •
             

              Stress-induced chest pain and/or ischemic ECG changes in the presence of transient/reversible abnormal myocardial perfusion and/or wall motion abnormality
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="4">
  <cell col="0" row="4" text="
           4. Evidence of impaired coronary microvascular function
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="4" text="



              •
             

              Impaired coronary flow reserve (cut-off values depending on methodology use between ≤2.0 and
              
              ≤
              
              2.5)
             



              •
             

              Coronary microvascular spasm, defined as reproduction of symptoms, ischemic ECG shifts but no epicardial spasm during acetylcholine testing.
             



              •
             

              Abnormal coronary microvascular resistance indices (e.g. IMR &gt;25, HMR ≥2.5
              
              mm Hg·cm-1·s) (69)
             



              •
             

              Coronary slow flow phenomenon
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
  </cell>
 </row>
 <statements>
  <statement id="0" text="• Ischemic ECG changes during an episode of chest pain • Stress-induced chest pain and/or ischemic ECG changes in the presence of transient/reversible abnormal myocardial perfusion and/or wall motion abnormality is in covadis criteria for microvascular angina" type="">
  </statement>
  <statement id="1" text="• Effort and/or rest angina • Angina equivalents (i.e. shortness of breath) is in covadis criteria for microvascular angina" type="">
  </statement>
  <statement id="2" text="The value • Impaired coronary flow reserve (cut-off values depending on methodology use between ≤2.0 and ≤ 2.5) • Coronary microvascular spasm, defined as reproduction of symptoms, ischemic ECG shifts but no epicardial spasm during acetylcholine testing. • Abnormal coronary microvascular resistance indices (e.g. IMR &gt;25, HMR ≥2.5 mm Hg·cm-1·s) (69) • Coronary slow flow phenomenon belongs to covadis criteria for microvascular angina" type="">
  </statement>
  <statement id="3" text="The value • CT coronary angiography (CTCA) • Invasive coronary angiography belongs to covadis criteria for microvascular angina" type="">
  </statement>
  <statement id="4" text="All the values in covadis criteria for microvascular angina are distinct." type="">
  </statement>
  <statement id="5" text="Covadis criteria for microvascular angina always has the same value." type="">
  </statement>
 </statements>
</Table 1>
